Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Common Equity (2016 - 2025)

CorMedix has reported Common Equity over the past 16 years, most recently at $405.3 million for Q4 2025.

  • Quarterly results put Common Equity at $405.3 million for Q4 2025, up 378.76% from a year ago — trailing twelve months through Dec 2025 was $405.3 million (up 378.76% YoY), and the annual figure for FY2025 was $405.3 million, up 378.76%.
  • Common Equity reached $405.3 million in Q4 2025 per CRMD's latest filing, up from $374.1 million in the prior quarter.
  • Across five years, Common Equity topped out at $405.3 million in Q4 2025 and bottomed at $46.2 million in Q2 2024.
  • Median Common Equity over the past 5 years was $66.1 million (2021), compared with a mean of $107.1 million.
  • The largest annual shift saw Common Equity soared 31764174.79% in 2021 before it dropped 29.43% in 2024.
  • Over 5 years, Common Equity stood at $62.8 million in 2021, then decreased by 12.32% to $55.1 million in 2022, then rose by 27.39% to $70.1 million in 2023, then grew by 20.69% to $84.7 million in 2024, then skyrocketed by 378.76% to $405.3 million in 2025.
  • Business Quant data shows Common Equity for CRMD at $405.3 million in Q4 2025, $374.1 million in Q3 2025, and $220.6 million in Q2 2025.